|Assessment Status||Rapid Review Complete|
|Drug||Relugolix with estradiol and norethisterone acetate|
|Indication||Is indicated for moderate to severe symptoms of uterine fibroids in adult women of reproductive age.|
|Rapid review commissioned||01/02/2022|
|Rapid review completed||03/02/2022|
|Rapid review outcome||A full HTA is not recommended. The NCPE recommends that relugolix CT not be considered for reimbursement at the submitted price *.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.